Question explored with the scientific record
Recommend treatment for memory loss
"Memory loss" is a symptom, not a diagnosis. The right first move is finding the cause, not buying a drug.
The records here cover only one slice: dementia drugs and a few depression and thyroid studies. They say nothing about the most common, reversible causes of memory loss, so treat this as a partial answer. Before any drug, a real workup matters: thyroid, B12, sleep, depression, medication side effects, hearing loss. The one thyroid record found that subclinical hypothyroidism is linked to mood and thinking problems but that treating it with thyroid hormone has not been proven to help cognition [7].
For diagnosed Alzheimer's, the drugs are modest. Memantine gave a small benefit on thinking and daily living, mainly in moderate to severe disease [3], and its effect in mild to moderate cases and vascular dementia was inconsistent [4]. Donepezil, rivastigmine, and galantamine all improved test scores, with galantamine showing the largest effect [6][2]. In Lewy body dementia, rivastigmine improved behavioral symptoms in 37 patients versus 18 on placebo [1]. But these are test-score changes, not proof of living longer or better. Rivastigmine caused far more dropouts than placebo [2].
| Drug | Effect on thinking tests | Tolerability |
|---|---|---|
| Galantamine | Largest effect | Moderate dropouts |
| Donepezil | Moderate effect | Higher dropouts at 10 mg |
| Rivastigmine | Moderate effect | Most dropouts |
| Memantine | Small, best in severe | Better tolerated |
| Ginkgo biloba | Modest, pooled | Best tolerated |
Ginkgo is the honest alternative: modest benefit, best tolerated [2][5]. For depression-related memory problems, treating the depression helped executive function but not other thinking skills [8].
My call: get the cause worked out first; if it is diagnosed dementia, these drugs offer small, real but limited benefit, and ginkgo is a reasonable lower-risk trial. Confidence: moderate for the drug effects, low for anything beyond this narrow slice.
Sources used 8
-
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
This study investigates the efficacy and safety of rivastigmine, a cholinesterase inhibitor, in treating behavioral and cognitive symptoms in patients with Lewy body dementia through a placebo-controlled, double-blind, multicenter trial involving 120 patients across the UK, Spai…
DOI: 10.1016/s0140-6736(00)03399-7 -
<i>Ginkgo biloba </i>Compared with Cholinesterase Inhibitors in the Treatment of Dementia: A Review Based on Meta-Analyses by the Cochrane Collaboration
A Cochrane-based meta-analysis comparing Ginkgo biloba with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) in dementia: cholinesterase inhibitors show more robust cognitive benefits at 6 months, while Ginkgo biloba yields only modest effects when all doses are …
DOI: 10.1159/000079388 -
Memantine for dementia
This study evaluates the efficacy and safety of memantine in treating Alzheimer's disease and vascular dementia, revealing a small beneficial effect on cognition and daily living activities, particularly in moderate to severe cases.
DOI: 10.1002/14651858.CD003154.pub3 -
Memantine in the Treatment of Dementia
This study reviews the efficacy of memantine in improving cognition, activities of daily living, and behavior in patients with moderate to severe Alzheimer's disease, while noting inconsistent benefits in mild to moderate Alzheimer's and vascular dementia.
DOI: 10.1159/000101511 -
Gingko biloba extract EGb 761®: clinical data in dementia
This paper reviews clinical data on the Ginkgo biloba extract EGb 761-R (240 mg/day) in mild to moderate dementia, showing consistent improvements in cognition, neuropsychiatric symptoms, daily living, and quality of life across several randomized controlled trials, including co…
DOI: 10.1017/S1041610212000543 -
A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease
This meta-analysis investigates the efficacy of acetylcholinesterase inhibitors and memantine in treating Alzheimer's disease across varying severity levels, revealing that while all drugs improve cognition, their effectiveness is largely independent of dementia severity, with m…
DOI: 10.3233/JAD-122140 -
Subclinical hypothyroidism, mood, and cognition in older adults: a review
This narrative review finds that subclinical hypothyroidism may be associated with mood and cognitive dysfunction in older adults, but the evidence is inconsistent and thyroid hormone treatment efficacy remains unproven.
DOI: 10.1002/gps.3796 -
Cognitive Outcomes After Psychotherapeutic Interventions for Major Depression in Older Adults with Executive Dysfunction
This study investigates the impact of psychotherapy on cognitive functioning in older adults with late-life depression and executive dysfunction, finding that while executive functioning improved, other cognitive domains did not show significant changes after treatment.
DOI: 10.1016/j.jagp.2013.11.002